Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 9,843 | 1,955 | 1,580 | 2,978 | 1,597 |
| Marketable Securities | 6,699 | 5,940 | 6,715 | 7,528 | 9,910 |
| Receivables | 426 | 135 | 254 | 480 | 770 |
| Other current assets | 717 | 2,046 | 2,633 | 2,253 | 1,921 |
| TOTAL | $17,685 | $10,076 | $11,182 | $13,239 | $14,198 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | 74 | 83 | 89 |
| Investments And Advances | 3,265 | 3,265 | 3,265 | 3,265 | 3,265 |
| Other Non-Current Assets | 0 | 0 | 0 | 42 | 86 |
| TOTAL | $3,265 | $3,265 | $3,339 | $3,390 | $3,440 |
| Total Assets | $20,950 | $13,341 | $14,521 | $16,629 | $17,638 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,514 | 1,554 | 1,765 | 2,750 | 2,091 |
| TOTAL | $2,514 | $1,554 | $1,765 | $2,750 | $2,091 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,514 | $1,554 | $1,765 | $2,750 | $2,091 |
| Shareholders' Equity | |||||
| Common Shares | 665 | 263 | 249 | 209 | 166 |
| Retained earnings | -197,260 | -195,346 | -194,227 | -192,952 | -190,936 |
| Other shareholders' equity | -342 | -435 | -455 | -454 | -697 |
| TOTAL | $18,436 | $11,787 | $12,756 | $13,879 | $15,457 |
| Total Liabilities And Equity | $20,950 | $13,341 | $14,521 | $16,629 | $17,548 |